XML 39 R28.htm IDEA: XBRL DOCUMENT v3.25.3

SEGMENTS (Tables)

9 Months Ended

Sep. 30, 2025

SEGMENTS [Abstract]

Summarized Financial Information Concerning Reportable Segments

Summarized financial information concerning reportable segments is shown in the following tables:

Three Months ended September 30, 2025
(in thousands)		ADMA BioManufacturing				Plasma Collection Centers				Total
Revenues		$	134,188			$	-			$	134,188
Cost of product revenue			58,406				192				58,598
Research and development			1,528				-				1,528
Plasma center operating expenses			-				1,272				1,272
Selling, marketing and distribution			8,150				-				8,150
Amortization of intangible assets			38				-				38
General and administrative expense			14,585				-				14,585
Other expense, net			(21	)			-				(21	)
Income (loss) before taxes			51,460				(1,464	)			49,996
Expenditures for additions to long-lived assets			14,652				292				14,944
Total assets			403,917				27,028				430,945
Reconciliation of revenues:
Segment revenue										$	134,188
License revenue											36
Consolidated revenues										$	134,224
Reconciliation of selling, general and administrative expense:
Segment selling, marketing and distribution expense										$	8,150
Segment general and administrative expense											14,585
Corporate general and administrative expense (a)											(959	)
Consolidated selling, general and administrative expense										$	21,776
Reconciliation of income before taxes:
Segment income before taxes										$	49,996
License revenue											36
Unallocated interest expense, primarily related to interest on senior debt (see Note 6)											(1,675	)
Unallocated interest income											376
Loss on extinguishment of debt											(2,177	)
Corporate general and administrative expense (a)											959
Consolidated income before taxes										$	47,515
Reconciliation of total assets:
Total segment assets										$	430,945
Corporate (b)											137,742
Consolidated total assets										$	568,687

(a) - Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.

(b) - Primarily consists of cash and deferred tax assets.

Nine Months ended September 30, 2025
(in thousands)		ADMA BioManufacturing				Plasma Collection Centers				Total
Revenues		$	369,852			$	1,050			$	370,902
Cost of product revenue			166,220				841				167,061
Research and development			3,386				-				3,386
Plasma center operating expenses			-				3,710				3,710
Selling, marketing and distribution			17,827				-				17,827
Amortization of intangible assets			93				-				93
General and administrative expense			44,688				-				44,688
Other expense, net			(195	)			-				(195	)
Income (loss) before taxes			137,443				(3,501	)			133,942
Expenditures for additions to long-lived assets			21,366				263				21,629
Total assets			403,917				27,028				430,945
Reconciliation of revenues:
Segment revenue										$	370,902
License revenue											108
Consolidated revenues										$	371,010
Reconciliation of selling, general and administrative expense:
Segment selling, marketing and distribution expense										$	17,827
Segment general and administrative expense											44,688
Corporate general and administrative expense (a)											5,553
Consolidated selling, general and administrative expense										$	68,068
Reconciliation of income (loss) before taxes:
Segment income before taxes										$	133,942
License revenue											108
Unallocated interest expense, primarily related to interest on senior debt (see Note 6)											(5,484	)
Unallocated interest income											1,384
Loss on extinguishment of debt											(3,336	)
Corporate general and administrative expense (a)											(5,553	)
Consolidated income before taxes										$	121,061
Reconciliation of total assets:
Total segment assets										$	430,945
Corporate (b)											137,742
Consolidated total assets										$	568,687

(a) - Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.

(b) - Primarily consists of cash and deferred tax assets.

Three Months Ended September 30, 2024
(in thousands)		ADMA BioManufacturing				Plasma Collection Centers				Total
Revenues		$	117,719			$	2,084			$	119,803
Cost of product revenue			58,156				2,024				60,180
Research and development			412				-				412
Plasma center operating expenses			-				1,021				1,021
Selling, marketing and distribution			5,900				-				5,900
Amortization of intangible assets			28				-				28
General and administrative expense			3,988				-				3,988
Other expense, net			(56	)							(56	)
Income (loss) before taxes			49,179				(961	)			48,218
Expenditures for additions to long-lived assets			1,067				9				1,076
Total assets			266,456				33,191				299,647
Reconciliation of revenues:
Segment revenue										$	119,803
License revenue											36
Consolidated revenues										$	119,839
Reconciliation of selling, general and administrative expense:
Segment selling, marketing and distribution expense										$	5,900
Segment general and administrative expense											3,988
Corporate general and administrative expense (a)											8,672
Consolidated selling, general and administrative expense										$	18,560
Reconciliation of income (loss) before taxes:
Segment income before taxes										$	48,218
License revenue											36
Unallocated interest expense, primarily related to interest on senior debt (see Note 6)											(3,499	)
Unallocated interest income											666
Corporate general and administrative expense (a)											(8,672	)
Consolidated income before taxes										$	36,749
Reconciliation of total assets:
Total segment assets										$	299,647
Corporate (b)											90,971
Consolidated total assets										$	390,618

(a) - Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.

(b) - Primarily consists of cash and deferred tax assets.

Nine Months Ended September 30, 2024
(in thousands)		ADMA BioManufacturing				Plasma Collection Centers				Total
Revenues		$	304,016			$	4,781			$	308,797
Cost of product revenue			147,619				5,066				152,685
Research and development			1,422				-				1,422
Plasma center operating expenses			-				2,968				2,968
Selling, marketing and distribution			13,374				-				13,374
Amortization of intangible assets			363				-				363
General and administrative expense			18,276				-				18,276
Other expense, net			(103	)			(4	)			(107	)
Income (loss) before taxes			122,859				(3,257	)			119,602
Expenditures for additions to long-lived assets			5,720				105				5,825
Total assets			266,456				33,191				299,647
Reconciliation of revenues:
Segment revenue										$	308,797
License revenue											108
Consolidated revenues										$	308,905
Reconciliation of selling, general and administrative expense:
Segment selling, marketing and distribution expense										$	13,374
Segment general and administrative expense											18,276
Corporate general and administrative expense (a)											19,157
Consolidated selling, general and administrative expense										$	50,807
Reconciliation of income (loss) before taxes:
Segment income before taxes										$	119,602
License revenue											108
Unallocated interest expense, primarily related to interest on senior debt (see Note 6)											(11,051	)
Unallocated interest income											1,499
Corporate general and administrative expense (a)											(19,157	)
Consolidated income before taxes										$	91,001
Reconciliation of total assets:
Total segment assets										$	299,647
Corporate (b)											90,971
Consolidated total assets										$	390,618

(a) - Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.

(b) - Primarily consists of cash and deferred tax assets.

Net Revenues According to Geographic Area

Net revenues according to geographic area, based on the location of where the product is shipped, were as follows:

		Three Months Ended September 30,								Nine Months Ended September 30,
(in thousands)		2025				2024				2025				2024
United States		$	133,978			$	114,748			$	366,692			$	295,465
International			246				5,091				4,318				13,440
Total revenues		$	134,224			$	119,839			$	371,010			$	308,905

X

- Definition

Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration